Erica Fischer-Cartlidge Discusses Oral Mucositis Treatment for Patients Taking an mTOR Inhibitor

Video
Conferences|ONS Annual Congress

Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.

Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.

Fischer-Cartlidge says when oral mucositis presents in a patient taking an mTOR inhibitor, it looks and acts differently than oral mucositis in patients receiving chemotherapy.

Fortunately, the oral mucositis in patients taking an mTOR inhibitor responds to steroids better than oral mucositis that presents in patients receiving chemotherapy. The steroid actually healed the oral mucositis instead of just controlling it, Fishcer-Cartlidge says, reducing the need for dose reduction.

<<<

View more from the 40th Annual ONS Congress

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
Photo of a man wearing glasses and a suit in front of a blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
Photo of Hope Rugo, MD
Image of a woman with blond hair in front of a dark blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Related Content
Graphic of malignant B cells

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

Chris Ryan
July 30th 2025
Article

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Line illustration of a pair of kidneys with a tumor on the left kidney

Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

Russ Conroy
July 21st 2025
Article

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

The Vitals

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

Lindsay Fischer
June 1st 2023
Podcast

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Graphic of a kidney

Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

Ashling Wahner
July 18th 2025
Article

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

Graphic of a breast with a tumor

Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

Jax DiEugenio
July 14th 2025
Article

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.